London-based Automata Technologies is at the forefront of a shift in life sciences laboratories, developing infrastructure designed to integrate robotics and software with existing scientific instruments. This connected approach is emerging as a critical factor in preparing labs for the widespread application of artificial intelligence (AI).
For decades, the foundation of scientific discovery – from new cancer drugs to diagnostic tests and vaccines – has often relied on thousands of experiments, meticulously run and refined. Much of this work has been conducted manually, with scientists spending extensive hours preparing and moving samples before recording results. These processes demand extraordinary precision but consume valuable time that could otherwise be dedicated to critical thinking, interpreting findings, and strategising next experimental steps.
Automata Technologies, a British company, is addressing these challenges by developing lab automation infrastructure. Their system integrates robotics and software with existing scientific instruments, creating a connected environment crucial for life sciences organisations looking to leverage AI.
In practice, co-ordinating instruments, workflows, and data through such infrastructure can significantly increase experimental throughput. It also creates "walkaway time," allowing experiments to run more consistently and, in some cases, without constant human supervision. This enables laboratories to test a greater number of ideas and identify promising results more rapidly, without requiring equivalent increases in headcount or facilities. The ultimate aim is to shorten the path to new medicines and expand access to diagnostic testing.
For many organisations within the pharmaceutical, biotechnology, and diagnostics sectors, the question has evolved from whether to automate to how to implement automation effectively. These organisations face increasing pressure to accelerate development, generate more reliable data, and maximise output from existing personnel and resources. The advent of AI has further underscored this urgency; while AI can analyse vast datasets and suggest future experiments, its full value can only be realised if laboratories are equipped to reliably execute those experiments and return high-quality, usable results.
However, much of the current lab automation landscape is not adequately equipped for this integrated future. Existing equipment often automates individual stages of an experiment but may not communicate seamlessly with preceding or subsequent stages. This can leave scientists responsible for manually transferring samples and information between disparate systems. Furthermore, vendor lock-in can exacerbate these issues, trapping labs in closed ecosystems that are difficult to adapt as scientific requirements and AI capabilities evolve.
Automata Technologies has structured its approach to bridge these gaps. Rather than introducing another isolated tool, the company operates on the principle that automation delivers maximum value when it functions as a connected system, not merely a collection of automated steps. This philosophy guides Automata’s work across both commercial and academic life sciences, supporting scientists conducting experiments as well as the R&D and operations leaders overseeing wider lab performance and scalability.
The company’s strategy is built upon three core principles:
- **Full Integration:** Automata emphasises the need for instruments, workflows, and data to connect end-to-end, regardless of the original equipment vendor. This flexibility allows labs to adapt their equipment and processes over time without being restricted to a single manufacturer’s ecosystem.
- **Ease of Use:** The system is designed to allow scientists and automation engineers to work collaboratively within the same framework without unnecessary friction. This requires tools that offer sufficient depth for specialists while remaining accessible to all personnel involved in the workflow.
- **AI Readiness:** For Automata, AI readiness extends beyond simply labelling a product as "AI-powered." It involves building the structured data and flexible architecture necessary for AI models to be meaningfully and effectively applied to lab operations.
These principles converge in Automata’s LINQ platform, which integrates modular lab hardware, orchestration software for coordinating instruments and workflows, and an open data architecture into a unified system.
The overarching objective of this automation is not merely automation itself, but to facilitate a fundamental shift towards lab operations that are more reliable, more scalable, and increasingly autonomous over time. As AI continues to reshape the life sciences sector, Automata’s position is that the true differentiator for future success lies not in any single instrument or feature, but in a laboratory's capacity to operate as a fully integrated, usable, and AI-ready connected whole.
